Nuvilex (NASDAQ:PMCB) Posts Earnings Results

Nuvilex (NASDAQ:PMCB) released its quarterly earnings results on Tuesday. The company reported ($0.17) earnings per share for the quarter, FiscalAI reports.

Nuvilex Trading Up 1.4%

NASDAQ PMCB opened at $0.70 on Thursday. The business’s 50-day moving average price is $0.77 and its two-hundred day moving average price is $0.86. Nuvilex has a 12 month low of $0.63 and a 12 month high of $1.72. The firm has a market capitalization of $7.52 million, a PE ratio of -0.63 and a beta of 0.33.

Analyst Upgrades and Downgrades

PMCB has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Nuvilex in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of Nuvilex to a “sell” rating in a research report on Saturday, January 31st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Nuvilex has a consensus rating of “Sell”.

Insider Buying and Selling at Nuvilex

In related news, CEO Joshua Silverman acquired 40,000 shares of the stock in a transaction dated Wednesday, January 7th. The stock was bought at an average cost of $0.83 per share, for a total transaction of $33,200.00. Following the completion of the transaction, the chief executive officer directly owned 416,250 shares of the company’s stock, valued at $345,487.50. The trade was a 10.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders bought a total of 110,000 shares of company stock valued at $89,000 over the last ninety days. Corporate insiders own 10.98% of the company’s stock.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.